Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals, Inc. (SYRS) has been a biopharmaceutical company focused on developing tamibarotene, an oral, selective retinoic acid receptor alpha (RARα) agonist, for the frontline treatment of hematologic malignancies. Company news has centered on higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML) in patients whose disease exhibits RARA gene overexpression.
News coverage for Syros includes clinical trial updates from key studies such as the Phase 3 SELECT-MDS-1 trial in HR-MDS and the Phase 2 SELECT-AML-1 trial in AML. These announcements have detailed trial designs, interim analyses, complete response (CR) and CRi rates, and decisions to continue or discontinue enrollment based on prespecified futility analyses. Press releases have also discussed the safety profile of tamibarotene in combination regimens and the company’s interpretation of clinical data.
Financial and corporate updates form another important category of news for SYRS. Syros has reported quarterly financial results, described its cash position and operating expense trends, and outlined expectations for how long existing cash and cash equivalents may fund operations. The company has also provided business updates around pre-commercial activities, conference presentations, and webcast events focused on HR-MDS disease biology and the treatment landscape.
More recent news has highlighted material corporate developments, including the failure of the SELECT-MDS-1 trial to meet its primary endpoint, the resulting event of default under Syros’ loan agreement, and the company’s decision to operate as a wind-down. Additional announcements describe the Board’s approval of a voluntary delisting from Nasdaq, plans to deregister the common stock, and the sale of tamibarotene-related clinical and non-clinical assets to Rege Nephro Co., Ltd. Investors and observers can use the SYRS news stream to follow this transition from late-stage clinical development activities to an orderly wind down of operations.
Syros Pharmaceuticals (NASDAQ: SYRS) announced it will present new clinical data from its Phase 2 trial of SY-1425, a selective RARα agonist, at the 62nd ASH Annual Meeting on December 5-8, 2020. The trial focuses on RARA-positive patients with relapsed or refractory acute myeloid leukemia (AML). Oral presentations will highlight promising data on SY-1425 combined with azacitidine, showcasing a high complete response rate and rapid onset for newly diagnosed unfit AML patients. Additionally, poster presentations will address resistance to venetoclax among RARA-positive patients.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call on November 5, 2020, at 4:30 p.m. ET, to report its Q3 2020 financial results and provide a corporate update. Investors can join the call by dialing 866-595-4538 (domestic) or 636-812-6496 (international), with the conference ID 1088286. A webcast will also be available on Syros' website, offering an archived replay for 30 days post-call. The company is focused on developing innovative treatments for diseases through gene expression control, with key programs including SY-1425 and SY-5609 in clinical trials.
Syros Pharmaceuticals (NASDAQ:SYRS) announced initial safety, pharmacokinetics, and pharmacodynamics data from its ongoing Phase 1 trial of SY-5609, a selective oral CDK7 inhibitor for solid tumors. Early results show proof of mechanism and establish a maximum tolerated dose (MTD) of 3 mg for daily dosing. Among 17 enrolled patients, SY-5609 showed dose-dependent increases in POLR2A mRNA, indicating CDK7 activity. The trial is expanding to include more cancer types, including pancreatic and lung cancer. Future data is expected in mid-2021.
Syros Pharmaceuticals (NASDAQ:SYRS) has announced the upcoming presentation of initial data from its Phase 1 clinical trial of SY-5609, an oral CDK7 inhibitor targeting select solid tumors. This data, focusing on safety and pharmacodynamics, will be showcased during a poster session at the 32nd EORTC-NCI-AACR Symposium on October 24-25, 2020. The presentation aims to demonstrate dose-dependent pharmacodynamic activity in patients. The abstract is currently available on the conference website, with on-demand viewing options starting from October 24.